<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800315</url>
  </required_header>
  <id_info>
    <org_study_id>CC-93538-AD-001</org_study_id>
    <secondary_id>1111-1260-5462</secondary_id>
    <secondary_id>2020-005212-22</secondary_id>
    <nct_id>NCT04800315</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 2, Multicenter, Global, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of 3 dose regimen of&#xD;
      CC-93538 in adult participants with moderate to severe Atopic Dermatitis (AD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2021</start_date>
  <completion_date type="Anticipated">August 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 8, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in EASI from Baseline at Week 16</measure>
    <time_frame>Up to week 16</time_frame>
    <description>The Eczema Area and Severity Index (EASI) is a composite scoring system assessed by the Investigator based on the proportion of each of the 4 body regions (head and neck, upper limbs, lower limbs, and trunk) affected with Atopic Dermatitis (AD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with an vIGAAD score from Baseline at Week 16</measure>
    <time_frame>Up to week 16</time_frame>
    <description>The Validated Investigator Global Assessment (vIGA)-AD is a validated 5-point assessment intended to assess the global severities of key acute clinical signs of AD, including erythema, induration/papulation, oozing/crusting (lichenification excluded).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with at least a 75% improvement from Baseline in Eczema Area and Severity Index (EASI-75) at Week 16</measure>
    <time_frame>Up to week 16</time_frame>
    <description>The EASI is a composite scoring system assessed by the Investigator based on the proportion of each of the 4 body regions (head and neck, upper limbs, lower limbs, and trunk) affected with AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from Baseline in Pruritus Numerical Rating Scale (NRS) at Week 16</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Pruritus NRS is a single item, participant reported outcome (PRO) of itch severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Pruritus NRS change of ≥ 4 points from Baseline at Week 16</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Pruritus NRS is a single item, participant reported outcome (PRO) of itch severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to achieve at least 4 points of improvement in the severity of pruritus NRS scale in the first 16 weeks of treatment</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Pruritus NRS is a single item, participant reported outcome (PRO) of itch severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with at least a 90% improvement from Baseline in Eczema Area and Severity Index (EASI-90) at Week 16</measure>
    <time_frame>Up to week 16</time_frame>
    <description>The Eczema Area and Severity Index (EASI) is a composite scoring system assessed by the Investigator based on the proportion of each of the 4 body regions (head and neck, upper limbs, lower limbs, and trunk) affected with Atopic Dermatitis (AD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in SCORAD Scores from Baseline at Week 16</measure>
    <time_frame>Up to week 16</time_frame>
    <description>The Scoring Atopic Dermatitis Index (SCORAD) is a validated scoring index for atopic dermatitis, which combines extent (0 to 100), severity (0 to 18), and subjective symptoms (0 to 20) based on pruritus and sleep loss, each scored (0 to 10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in BSA involved with AD from baseline at Week 16</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Percentage body surface area of the skin that displays signs or symptoms consistent with atopic dermatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to week 32</time_frame>
    <description>An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Immunogenicity through measurement of serum concentrations of anti-drug antibodies to CC-93538</measure>
    <time_frame>Up to week 32</time_frame>
    <description>Evaluated by the presence of anti-drug antibodies to CC-93538</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cthrough</measure>
    <time_frame>Up to week 32</time_frame>
    <description>Serum trough concentration of CC-93538</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>Dose 1: CC-93538 SC QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of CC-93538 Subcutaneous (SC) Once weekly (QW) for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2: CC-93538 and Placebo SC Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting at the baseline visit, active IP will be administered. On the alternate weeks, placebo will be administered to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3: CC-93538 and Placebo SC Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting at the baseline visit, active IP and matching placebo will be administered.&#xD;
On the alternate weeks, placebo will be administered weekly to maintain the blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SC QW</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of placebo each week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-93538</intervention_name>
    <description>Subcutaneous once weekly</description>
    <arm_group_label>Dose 1: CC-93538 SC QW</arm_group_label>
    <arm_group_label>Dose 2: CC-93538 and Placebo SC Q2W</arm_group_label>
    <arm_group_label>Dose 3: CC-93538 and Placebo SC Q2W</arm_group_label>
    <other_name>RPC4064</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous Every other week</description>
    <arm_group_label>Dose 2: CC-93538 and Placebo SC Q2W</arm_group_label>
    <arm_group_label>Dose 3: CC-93538 and Placebo SC Q2W</arm_group_label>
    <arm_group_label>Placebo SC QW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must satisfy the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Participant must be ≥ 18 years and ≤ 75 years of age and have a body weight of ≥ 40 kg&#xD;
             (88.2 lb) at the time of signing the informed consent form (ICF).&#xD;
&#xD;
          2. Participant has chronic atopic dermatitis (AD) as defined by Hanifin and Rajka that&#xD;
             has been present for ≥ 1 year prior to the baseline visit (Day 1).&#xD;
&#xD;
          3. Participant has moderate to severe, active, and symptomatic AD defined by meeting all&#xD;
             of the following criteria on the day of the baseline visit (Day 1):&#xD;
&#xD;
               1. Body Surface Area (BSA) ≥ 10%, and&#xD;
&#xD;
               2. EASI score ≥ 16, and&#xD;
&#xD;
               3. vIGA-AD ≥ 3, and&#xD;
&#xD;
               4. Pruritus Numeric Rating Scale (NRS) severity score ≥ 4.&#xD;
&#xD;
          4. Participant must have a documented history of inadequate response to treatment with&#xD;
             topical medications for at least 4 weeks, unless topical treatments are otherwise&#xD;
             medically inadvisable or has required systemic therapy for control of disease.&#xD;
&#xD;
          5. Participant must be willing to apply a stable dose of topical emollient (eg,&#xD;
             over-the-counter moisturizer, non-medicated emollient, etc.) twice daily for ≥ 7 days&#xD;
             prior to the Baseline visit and continue application throughout the study.&#xD;
&#xD;
          6. Participant must commit to avoid prolonged exposure to the sun and not to use tanning&#xD;
             booths, sun lamps or other ultraviolet light sources during the study.&#xD;
&#xD;
          7. Participants currently receiving concomitant medications for any reason other than AD,&#xD;
             such as inhaled corticosteroids, leukotriene receptor antagonists (eg, montelukast),&#xD;
             or mast cell stabilizers (eg, cromolyn sodium) for asthma, must be on a stable&#xD;
             regimen, which is defined as not starting a new drug, changing, or stopping dosage&#xD;
             within 7 days or 5 half-lives (whichever is longer) prior to Day 1 and through the&#xD;
             treatment duration of the study.&#xD;
&#xD;
          8. Female participants of childbearing potential must agree to practice a highly&#xD;
             effective method of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The presence of any of the following will exclude a participant from enrollment:&#xD;
             Evidence of an active and/or concurrent inflammatory skin condition (eg, seborrheic&#xD;
             dermatitis, psoriasis, acute allergic contact dermatitis, etc.) that would interfere&#xD;
             with the Investigator or participant-driven evaluations of AD.&#xD;
&#xD;
          2. Evidence of acute AD flare between the Screening and Baseline/ Randomization (eg,&#xD;
             doubling of the EASI score between Screening and Baseline).&#xD;
&#xD;
          3. Use of topical treatments that could affect the assessment of AD (eg, corticosteroids,&#xD;
             calcineurin inhibitors, tars, antibiotic creams, topical antihistamines) within 7 days&#xD;
             of the Day 1 visit.&#xD;
&#xD;
          4. Received phototherapy narrowband UVB (NB-UVB) or broad band phototherapy within 4&#xD;
             weeks prior to the Baseline visit.&#xD;
&#xD;
          5. Evidence of immunosuppression, participant is receiving, or has received systemic&#xD;
             immunosuppressive or immunomodulating drugs (eg, azathioprine, cyclosporine, systemic&#xD;
             corticosteroids, interferon gamma (IFN-γ), Janus kinase inhibitors, methotrexate,&#xD;
             mycophenolate-mofetil, etc.) within 4 weeks prior to the Baseline visit.&#xD;
&#xD;
          6. Treatment with immunomodulatory biologics&#xD;
&#xD;
          7. Concurrent treatment with another IP&#xD;
&#xD;
          8. Received a live attenuated vaccine within 1 month prior to the first Screening Visit&#xD;
             or anticipates the need to be vaccinated with a live attenuated vaccine during the&#xD;
             study.&#xD;
&#xD;
          9. Active parasitic/helminthic infection or a suspected parasitic/helminthic infection.&#xD;
&#xD;
         10. Ongoing infection&#xD;
&#xD;
         11. A history of idiopathic anaphylaxis or a major immunologic reaction (such as&#xD;
             anaphylactic reaction, anaphylactoid reaction, or serum sickness) to an immunoglobulin&#xD;
             G (IgG) containing agent. A known hypersensitivity to any ingredient in the&#xD;
             investigational product (IP) is also exclusionary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Draikiwicz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@bms.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cahaba Dermatology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913-6440</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Total Vein and Skin, LLC</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palm Beach Dermatology Group</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33484-6500</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acevedo Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142-2946</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GCP Global Clinical Professionals</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624-2038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metabolic Research Institute Inc</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401-3430</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aeroallergy Research Labs of Savannah</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406-2668</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-4546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sneeze Wheeze and Itch Associates LLC</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702-5115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Clarksville</city>
        <state>Indiana</state>
        <zip>47129-2201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Randall Dermatology</name>
      <address>
        <city>West Lafayette</city>
        <state>Indiana</state>
        <zip>47906-1569</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Randall Dermatology - Westfield Campus</name>
      <address>
        <city>Westfield</city>
        <state>Indiana</state>
        <zip>46074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansas City Dermatology P.A.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215-2377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>DermAssociates</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902-5006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Research Clarkston/Clarkston Dermatology</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Specialists PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JDR Dermatology Research, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skin Laser and Surgery Specialists of New York and New Jersey LLC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601-1974</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021-5506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DermResearchCenter of New York, Inc.</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069-6301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute PC - CRN - PPDS</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136-8303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>International Clinical Research</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Partners LLC</name>
      <address>
        <city>Henrico</city>
        <state>Virginia</state>
        <zip>23233-1487</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West End Dermatology Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233-1436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute for Skin Advancement</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3A 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rao Dermatology</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Chih-ho Hong Medical Inc.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research Inc.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P IX3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DermEdge</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5H 1G9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Centre for Clinical Trials Inc.</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermatologique du Quebec Metropolitain CRDQ</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kawashima Dermatology</name>
      <address>
        <city>Ichikawa</city>
        <zip>272-0033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miyata Dermatology Clinic</name>
      <address>
        <city>Matsudo</city>
        <zip>271-0092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kozni ambulance Kutna Hora</name>
      <address>
        <city>Kutná Hora</city>
        <zip>284 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermamedica</name>
      <address>
        <city>Náchod</city>
        <zip>547 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CCBR Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Basic Research Czech Pardubice</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CCBR Czech Prague s.r.o.</name>
      <address>
        <city>Prague</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>FN Motol</name>
      <address>
        <city>Praha 5</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clintrial</name>
      <address>
        <city>Praha</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatologicka Ambulance MUDr. Petr Trestik</name>
      <address>
        <city>Svitavy</city>
        <zip>568 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka-shi, Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers</name>
      <address>
        <city>Fukuoka</city>
        <zip>815-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ichinomiya Municipal Hospital</name>
      <address>
        <city>Ichinomiya</city>
        <zip>491-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Itabashi-ku</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saruwatari Dermatology Clinic</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-0055</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamanashi Prefectual Central Hospital</name>
      <address>
        <city>Kofu</city>
        <zip>400-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto-City</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charme-Clinique</name>
      <address>
        <city>Matsudo</city>
        <zip>270-2223</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Takagi Dermatology</name>
      <address>
        <city>Obihiro</city>
        <zip>080-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nakatsu Hifuka Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>Osaka</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo Skin Clinic</name>
      <address>
        <city>Sapporo-shi, Hokkaido</city>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Kojinkai Housui Sogo Medical Clinic</name>
      <address>
        <city>Sapporo</city>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Medical University Hospital</name>
      <address>
        <city>Shinjuku</city>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nomura Dermatology Clinic</name>
      <address>
        <city>Yokohoma City, Kanagawa</city>
        <zip>221-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Copernicus Podmiot Leczniczy Sp. z o.o.</name>
      <address>
        <city>Gdansk</city>
        <zip>80-803</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Care Clinic</name>
      <address>
        <city>Katowice</city>
        <zip>40-568</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Angelius Provita</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Dermoklinika</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miejski Szpital Zespolony w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-229</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Zdybski</name>
      <address>
        <city>Ostrowiec Świętokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Laser Clinic Dermatologia Laserowa Medycyna Estetyczna</name>
      <address>
        <city>Szczecin</city>
        <zip>70-332</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia Szczecinskie Centrum Medyczne</name>
      <address>
        <city>Szczecin</city>
        <zip>71-434</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>High-Med Przychodnia Specjalistyczna</name>
      <address>
        <city>Warsaw</city>
        <zip>01-817</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Ambroziak Estederm</name>
      <address>
        <city>Warsaw</city>
        <zip>02-953</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia WroMedica</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniczny Szpital Wojewódzki nr 1 im. F. Chopina w Rzeszowie</name>
      <address>
        <city>Wrocław</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Gabinety Lekarskie DERMED</name>
      <address>
        <city>Łódź</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>Cendakimab</keyword>
  <keyword>CC-93538</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link:&#xD;
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>See Plan Description</ipd_time_frame>
    <ipd_access_criteria>See Plan Description</ipd_access_criteria>
    <ipd_url>https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

